Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback